From Yahoo Finance: 2025-04-22 09:52:00

1. Gilead Sciences, Inc. (NASDAQ:GILD) is among the cheap NASDAQ stocks favored by hedge funds. Tech sector faces major volatility due to tariffs on China. Large tech purchases have been downsized, leading to ongoing uncertainty and earnings cuts of about 10% predicted for internet and big tech companies.
2. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company with a forward P/E ratio of 13.24 and 74 hedge fund holders. Its HIV franchise saw $19.6 billion in 2024 sales, driven by Biktarvy and Descovy. Despite potential impact of Medicare Part D reform, Gilead expects 5% revenue growth in the HIV segment for 2025.
3. ClearBridge Value Strategy highlighted Gilead Sciences, Inc. (NASDAQ:GILD) in its Q1 2025 investor letter, noting strong earnings growth and promising developments in HIV prevention and cirrhosis treatment. While GILD ranks 9th on the list of cheap NASDAQ stocks, AI stocks may offer higher returns in a shorter time frame.
4. Find out about the best AI stocks to buy now and the top stocks recommended by billionaires at Insider Monkey. This article was originally published on Insider Monkey.

Read more: Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?